keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimer biomarker

keyword
https://www.readbyqxmd.com/read/28428473/technical-considerations-on-scanning-and-image-analysis-for-amyloid-pet-in-dementia
#1
Go Akamatsu, Akihito Ohnishi, Kazuki Aita, Yasuhiko Ikari, Yasuji Yamamoto, Michio Senda
Brain imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and positron emission tomography (PET), can provide essential and objective information for the early and differential diagnosis of dementia. Amyloid PET is especially useful to evaluate the amyloid-β pathological process as a biomarker of Alzheimer's disease. This article reviews critical points about technical considerations on the scanning and image analysis methods for amyloid PET...
2017: Nihon Hoshasen Gijutsu Gakkai Zasshi
https://www.readbyqxmd.com/read/28428166/vascular-cognitive-impairment-in-a-memory-clinic-population-rationale-and-design-of-the-utrecht-amsterdam-clinical-features-and-prognosis-in-vascular-cognitive-impairment-trace-vci-study
#2
EDITORIAL
Jooske Marije Funke Boomsma, Lieza Geertje Exalto, Frederik Barkhof, Esther van den Berg, Jeroen de Bresser, Rutger Heinen, Huiberdina Lena Koek, Niels Daniël Prins, Philip Scheltens, Henry Chanoch Weinstein, Wiesje Maria van der Flier, Geert Jan Biessels
BACKGROUND: Vascular Cognitive Impairment (VCI) refers to cognitive dysfunction due to vascular brain injury, as a single cause or in combination with other, often neurodegenerative, etiologies. VCI is a broad construct that captures a heterogeneous patient population both in terms of cognitive and noncognitive symptoms and in terms of etiology and prognosis. This provides a challenge when applying this construct in clinical practice. OBJECTIVE: This paper presents the rationale and design of the TRACE-VCI study, which investigates the clinical features and prognosis of VCI in a memory clinic setting...
April 19, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28428015/plasma-neurofilament-light-chain-levels-in-alzheimer-s-disease
#3
Wenjun Zhou, Jie Zhang, Fanlong Ye, Guangzheng Xu, Hang Su, Yindan Su, Xiangyang Zhang
Plasma neurofilament light (NFL) levels may be a marker of neuronal injury. We examined whether plasma NFL might be a potential biomarker for the prodromal and dementia stages of AD. Participants included 193 cognitively normal (CN), 198 amnestic mild cognitive impairment (aMCI) and 187 Alzheimer's disease (AD) individuals enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Plasma NFL levels were examined by the Single Molecule array (Simoa) technique. Our results showed significantly increased plasma NFL levels in both AD (50...
April 17, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28424619/retinal-and-circulating-mirnas-in-age-related-macular-degeneration-an-in-vivo-animal-and-human-study
#4
Giovanni L Romano, Chiara B M Platania, Filippo Drago, Salvatore Salomone, Marco Ragusa, Cristina Barbagallo, Cinzia Di Pietro, Michele Purrello, Michele Reibaldi, Teresio Avitabile, Antonio Longo, Claudio Bucolo
Age related macular degeneration (AMD) is the leading cause of blindness among people aged 50 and over. Retinal deposition of amyloid-β (Aβ) aggregates in AMD patients has suggested a potential link between AMD and Alzheimer's disease (AD). We have evaluated the differential retinal expression profile of miRNAs in a rat model of AMD elicited by Aβ. A serum profile of miRNAs in AMD patients has been also assessed using single TaqMan assay. Analysis of retina from rats intravitreally injected with Aβ revealed that miR-27a, miR-146a, and miR-155 were up-regulated in comparison to control rats...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28424614/relationship-between-cognitive-and-sleep-wake-variables-in-asymptomatic-offspring-of-patients-with-late-onset-alzheimer-s-disease
#5
Carolina Abulafia, Bárbara Duarte-Abritta, Mirta F Villarreal, María S Ladrón-de-Guevara, Celeste García, Geraldine Sequeyra, Gustavo Sevlever, Leticia Fiorentini, Karl-Jürgen Bär, Deborah R Gustafson, Daniel E Vigo, Salvador M Guinjoan
Early neuropathological changes characteristic of late-onset Alzheimer's disease (LOAD) involve brain stem and limbic structures that regulate neurovegetative functions, including sleep-wake rhythm. Indeed, sleep pattern is an emerging biomarker and a potential pathophysiological mechanism in LOAD. We hypothesized that cognitively asymptomatic, middle-aged offspring of patients with LOAD (O-LOAD) would display a series of circadian rhythm abnormalities prior to the onset of objective cognitive alterations. We tested 31 children of patients with LOAD (O-LOAD) and 19 healthy individuals without family history of Alzheimer's disease (control subjects, CS) with basic tests of cognitive function, as well as actigraphy measures of sleep-wake rhythm, cardiac autonomic function, and bodily temperature...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28424166/applying-fluid-biomarkers-to-alzheimer-s-disease
#6
Henrik Zetterberg
Alzheimer's disease (AD) is a common neurodegenerative disease that starts with a clinically silent phase of a decade or more during which brain pathologies accumulate predominantly in the medial temporal lobe but also elsewhere in the brain. Network dysfunction and clinical symptoms typically appear when senile plaque (amyloid β) and neurofibrillary tangle (tau) pathologies meet in the brain parenchyma, producing synapse and neuronal loss. For plaque and tangle pathologies, reliable fluid biomarkers have been developed...
April 19, 2017: American Journal of Physiology. Cell Physiology
https://www.readbyqxmd.com/read/28422821/how-the-cognitive-reserve-interacts-with-%C3%AE-amyloid-deposition-in-mitigating-fdg-metabolism-an-observational-study
#7
Elena Carapelle, Laura Serra, Sergio Modoni, Michele Falcone, Carlo Caltagirone, Marco Bozzali, Luigi Maria Specchio, Carlo Avolio
This observational study had the aim to assess the interaction between cognitive reserve (CR) and cerebrospinal fluid β-amyloid1-42 (Aβ1-42) in modulating brain [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) metabolism in patients with moderate Alzheimer disease (AD).Twenty-seven patients with probable AD and 25 neurological normal subjects (NNS) entered the study. All participants had an FDG-PET scan, and AD patients also received a lumbar puncture to measure Aβ1-42, 181p-tau, and Tau concentrations...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28421328/association-of-adiponectin-leptin-and-resistin-with-inflammatory-markers-and-obesity-in-dementia
#8
Małgorzata Bednarska-Makaruk, Ałła Graban, Anna Wiśniewska, Wanda Łojkowska, Anna Bochyńska, Magdalena Gugała-Iwaniuk, Ksenia Sławińska, Agnieszka Ługowska, Danuta Ryglewicz, Hanna Wehr
The aim of the study was to determine the role of adiponectin, leptin and resistin in various types of dementia and to investigate their association with inflammatory markers, insulin resistance and abdominal obesity. In 205 patients with dementia [89 with Alzheimer's disease (AD), 47 with vascular dementia (VaD), 69 with mixed dementia (MD)], 113 persons with mild cognitive impairment and in 107 controls serum adiponectin, leptin and resistin levels, pro-inflammatory [interleukin-6 (IL-6), C-reactive protein (hsCRP) and chitotriosidase] and anti-inflammatory (25-OH vitamin D, HDL-cholesterol and paraoxonase 1) markers, as well as glucose metabolism parameters (glucose, insulin and HOMA-IR) were determined...
April 18, 2017: Biogerontology
https://www.readbyqxmd.com/read/28420443/tau-phosphorylation-induced-by-severe-closed-head-traumatic-brain-injury-is-linked-to-the-cellular-prion-protein
#9
Richard Rubenstein, Binggong Chang, Natalia Grinkina, Eleanor Drummond, Peter Davies, Meir Ruditzky, Deep Sharma, Kevin Wang, Thomas Wisniewski
Studies in vivo and in vitro have suggested that the mechanism underlying Alzheimer's disease (AD) neuropathogenesis is initiated by an interaction between the cellular prion protein (PrP(C)) and amyloid-β oligomers (Aβo). This PrP(C)-Aβo complex activates Fyn kinase which, in turn, hyperphosphorylates tau (P-Tau) resulting in synaptic dysfunction, neuronal loss and cognitive deficits. AD transgenic mice lacking PrP(C) accumulate Aβ, but show normal survival and no loss of spatial learning and memory suggesting that PrP(C) functions downstream of Aβo production but upstream of intracellular toxicity within neurons...
April 18, 2017: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/28420323/study-protocol-insight-46-a-neuroscience-sub-study-of-the-mrc-national-survey-of-health-and-development
#10
Christopher A Lane, Thomas D Parker, Dave M Cash, Kirsty Macpherson, Elizabeth Donnachie, Heidi Murray-Smith, Anna Barnes, Suzie Barker, Daniel G Beasley, Jose Bras, David Brown, Ninon Burgos, Michelle Byford, M Jorge Cardoso, Ana Carvalho, Jessica Collins, Enrico De Vita, John C Dickson, Norah Epie, Miklos Espak, Susie M D Henley, Chandrashekar Hoskote, Michael Hutel, Jana Klimova, Ian B Malone, Pawel Markiewicz, Andrew Melbourne, Marc Modat, Anette Schrag, Sachit Shah, Nikhil Sharma, Carole H Sudre, David L Thomas, Andrew Wong, Hui Zhang, John Hardy, Henrik Zetterberg, Sebastien Ourselin, Sebastian J Crutch, Diana Kuh, Marcus Richards, Nick C Fox, Jonathan M Schott
BACKGROUND: Increasing age is the biggest risk factor for dementia, of which Alzheimer's disease is the commonest cause. The pathological changes underpinning Alzheimer's disease are thought to develop at least a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment - including β-amyloid depostion, vascular disease, network breakdown and atrophy - to be assessed repeatedly and non-invasively...
April 18, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28416790/a-meta-analysis-of-cerebrospinal-fluid-visinin-like-protein-1-in-alzheimers-disease-patients-relative-to-healthy-controls-and-mild-cognitive-impairment-patients
#11
Xiaohui Hu, Yan Yang, Daokai Gong
OBJECTIVE: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer`s disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. METHODS: "Visinin-like protein-1" and "alzheimer`s disease" were employed to search "PubMed", "Springer" and "Medline" databases until July 2016 and standard mean difference (Std.MD) was calculated. Besides, subgroup analysis and meta-regression were performed to explore the possible heterogeneity sources...
April 2017: Neurosciences: the Official Journal of the Pan Arab Union of Neurological Sciences
https://www.readbyqxmd.com/read/28413981/default-mode-network-connectivity-and-related-white-matter-disruption-in-type-2-diabetes-mellitus-patients-concurrent-with-amnestic-mild-cognitive-impairment
#12
Di Qi, Ailin Wang, Yaojing Chen, Kewei Chen, Sisi Zhang, Junying Zhang, Xin Li, Lin Ai, Zhanjun Zhang
BACKGROUND: As a risk factor for Alzheimer's disease (AD), Type 2 diabetes mellitus (T2DM) itself causes cognitive impairment and has higher prevalence of mild cognitive impairment (MCI). OBJECTIVE: The aim of this study was to explore the cognition especially the episodic memory difference, the DMN functional connectivity and DMN-related white matter integrity in patients with both T2DM and amnestic MCI (T2DM-MCI) as compared to patients with T2DM only. METHOD: Focusing especially on T2DM population, we investigated the default mode network (DMN) through resting functional magnetic resonance imaging among 22 elderly T2DM-MCI patients and 24 elderly T2DM patients...
April 17, 2017: Current Alzheimer Research
https://www.readbyqxmd.com/read/28413821/cerebrospinal-fluid-biomarkers-for-alzheimer-s-disease-in-down-syndrome
#13
Alain D Dekker, Juan Fortea, Rafael Blesa, Peter P De Deyn
Down syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid-β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in all DS individuals. Dementia diagnostics is complex in this population, illustrating the great need for predictive biomarkers. Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-β42, high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28413716/data-driven-regions-of-interest-for-longitudinal-change-in-three-variants-of-frontotemporal-lobar-degeneration
#14
Richard J Binney, Aleksandr Pankov, Gabriel Marx, Xuanzie He, Faye McKenna, Adam M Staffaroni, John Kornak, Suneth Attygalle, Adam L Boxer, Norbert Schuff, Maria-Luisa Gorno-Tempini, Michael W Weiner, Joel H Kramer, Bruce L Miller, Howard J Rosen
INTRODUCTION: Longitudinal imaging of neurodegenerative disorders is a potentially powerful biomarker for use in clinical trials. In Alzheimer's disease, studies have demonstrated that empirically derived regions of interest (ROIs) can provide more reliable measurement of disease progression compared with anatomically defined ROIs. METHODS: We set out to derive ROIs with optimal effect size for quantifying longitudinal change in a hypothetical clinical trial by comparing atrophy rates in 44 patients with behavioral variant of frontotemporal dementia (bvFTD), 30 with the semantic variant primary progressive aphasia (svPPA), and 26 with the nonfluent variant PPA (nfvPPA) to atrophy in 97 cognitively healthy controls...
April 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28412600/dna-methylation-changes-at-trem2-intron-1-and-trem2-mrna-expression-in-patients-with-alzheimer-s-disease
#15
Yuki Ozaki, Yuta Yoshino, Kiyohiro Yamazaki, Tomoko Sao, Yoko Mori, Shinichiro Ochi, Taku Yoshida, Takaaki Mori, Jun-Ichi Iga, Shu-Ichi Ueno
OBJECTIVES: Recent genome-wide association studies revealed that Triggering receptor expressed on myeloid cells 2 (TREM2) was associated with Alzheimer's disease (AD) and other neurodegenerative diseases. We previously reported that TREM2 mRNA is highly expressed in leukocytes of AD patients compared to those in healthy controls. However, the mechanism of TREM2 expression change is still not known. In this study, we examined the involvement of the DNA methylation status of TREM2 in its high gene expression...
April 11, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28411132/methyl-jasmonate-attenuates-memory-dysfunction-and-decreases-brain-levels-of-biomarkers-of-neuroinflammation-induced-by-lipopolysaccharide-in-mice
#16
Umukoro Solomon, Eduviere Anthony Taghogho
Neuroinflammation plays a central role in the etiology and progression of Alzheimer's disease (AD), a neurodegenerative disorder, characterized by a gradual loss of memory functions. Thus, it has been proposed that agents that could reduce inflammatory processes in AD brains might be useful for the treatment of the disease. Methyl jasmonate (MJ) is a bioactive compound, which has been reported to exhibit anti-amnesic and in vitro anti-inflammatory activities. In this study, we further examine its effects on the brain levels of biomarkers of neuroinflammation in lipopolysaccharide (LPS)-induced memory deficits in mice...
April 11, 2017: Brain Research Bulletin
https://www.readbyqxmd.com/read/28409746/the-role-of-adam10-in-alzheimer-s-disease
#17
Xiang-Zhen Yuan, Sen Sun, Chen-Chen Tan, Jin-Tai Yu, Lan Tan
As a member of the A Disintegrin And Metalloproteinase (ADAM) family, ADAM10 has been identified as the constitutive α-secretase in the process of amyloid-β protein precursor (AβPP) cleavage and plays a critical role in reducing the generation of the amyloid-β (Aβ) peptides. Recent studies have demonstrated its beneficial role in alleviating the pathologic impairment in Alzheimer's disease (AD) both in vitro and in vivo. However, the role of ADAM10 in AD and the underlying molecular mechanisms are still not well established...
April 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28408880/a-bayesian-model-for-the-prediction-and-early-diagnosis-of-alzheimer-s-disease
#18
Athanasios Alexiou, Vasileios D Mantzavinos, Nigel H Greig, Mohammad A Kamal
Alzheimer's disease treatment is still an open problem. The diversity of symptoms, the alterations in common pathophysiology, the existence of asymptomatic cases, the different types of sporadic and familial Alzheimer's and their relevance with other types of dementia and comorbidities, have already created a myth-fear against the leading disease of the twenty first century. Many failed latest clinical trials and novel medications have revealed the early diagnosis as the most critical treatment solution, even though scientists tested the amyloid hypothesis and few related drugs...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28407377/biomarkers-of-microvascular-endothelial-dysfunction-predict-incident-dementia-a-population-based-prospective-study
#19
H Holm, K Nägga, E D Nilsson, F Ricci, O Melander, O Hansson, E Bachus, M Magnusson, A Fedorowski
BACKGROUND: Cerebral endothelial dysfunction occurs in a spectrum of neurodegenerative diseases. Whether biomarkers of microvascular endothelial dysfunction can predict dementia is largely unknown. We explored the longitudinal association of midregional pro-atrial natriuretic peptide (MR-proANP), C-terminal endothelin-1 (CT-proET-1) and midregional pro-adrenomedullin (MR-proADM) with dementia and subtypes among community-dwelling older adults. METHODS: A population-based cohort of 5,347 individuals (men, 70%; age, 69±6 years) without prevalent dementia provided plasma for determination of MR-proANP, CT-proET-1 and MR-proADM...
April 13, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28406978/combined-assessment-of-serum-folate-and-hemoglobin-as-biomarkers-of-brain-amyloid-%C3%AE-accumulation
#20
Takuma Yoshinaga, Hiroto Nishimata, Yoriko Kajiya, Shunichi Yokoyama
A relationship between Alzheimer's disease (AD) and folate has been reported. Amyloid positron emission tomography (PET) is currently one of the most reliable biomarkers for AD. We investigated the correlation between serum folate levels and amyloid imaging to clarify whether serum folate could be a biomarker for AD. We also examined the usefulness of a combined assessment of serum folate levels and red blood cell hemoglobin content. Apolipoprotein E (APOE) gene polymorphisms were also assessed. Serum folate levels and hemoglobin content were evaluated by receiver operating characteristic analysis for their diagnostic capability as AD biomarkers relating to brain amyloid β accumulation...
2017: PloS One
keyword
keyword
16714
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"